Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 209Stomach Neoplasms 37Neoplasm Metastasis 26Neoplasms 18HER2-positive Breast Cancer 14Colorectal Neoplasms 14Carcinoma, Non-Small-Cell Lung 10Brain Neoplasms 10Esophageal Neoplasms 5Triple Negative Breast Neoplasms 4Squamous Cell Carcinoma of Head and Neck 4Pancreatic Neoplasms 4Ovarian Neoplasms 4Endometrial Neoplasms 4Adenocarcinoma Of Esophagus 4Uterine Cervical Neoplasms 3Urologic Neoplasms 3Lung Neoplasms 3Head and Neck Neoplasms 3HER2-positive Gastric Cancer 3Carcinoma 3Breast Cancer Metastatic 3Urinary Bladder Neoplasms 2Solid Tumors 2Sarcoma 2Parkinson Disease 4, Autosomal Dominant Lewy Body 2Melanoma 2HER2-positive Early Breast Cancer 2Cholangiocarcinoma 2Breast Diseases 2

Interventions

Trastuzumab 1Paclitaxel 1HM781-36B 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × HER-2 Positive Advanced Gastric Cancer × Trastuzumab × Clear all
NCT01746771 2016-03-03

A Phase I-II Study of HM781-36B Combined With Paclitaxel and Trastuzumab in HER-2 Positive Advanced Gastric Cancer

Hanmi Pharmaceutical Company Limited

Phase 1/2 Completed
44 enrolled
Gastrointestinal

HER-2 Positive Advanced Gastric Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡